ÇEKİÇ, Ş. Et Al. 2018. Vedolizumab treatment in patient with XLA, is it safe and efficient?. Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI) , (Munich, Germany), 768-769.

ÇEKİÇ, Ş., Ozgur, T., Karali, Y., Ozkan, T., & Kilic, S. Ş., (2018). Vedolizumab treatment in patient with XLA, is it safe and efficient? . Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI) (pp.768-769). Munich, Germany

ÇEKİÇ, ŞÜKRÜ Et Al. "Vedolizumab treatment in patient with XLA, is it safe and efficient?," Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI), Munich, Germany, 2018

ÇEKİÇ, ŞÜKRÜ Et Al. "Vedolizumab treatment in patient with XLA, is it safe and efficient?." Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI) , Munich, Germany, pp.768-769, 2018

ÇEKİÇ, Ş. Et Al. (2018) . "Vedolizumab treatment in patient with XLA, is it safe and efficient?." Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI) , Munich, Germany, pp.768-769.

@conferencepaper{conferencepaper, author={ŞÜKRÜ ÇEKİÇ Et Al. }, title={Vedolizumab treatment in patient with XLA, is it safe and efficient?}, congress name={Congress of the European-Academy-of-Allergy-and-Clinical-Immunology (EAACI)}, city={Munich}, country={Germany}, year={2018}, pages={768-769} }